

רופא/ה, רוקח/ת נכבד/ה,

Enbrel 50 mg - ו- Enbrel 25 mg solution for injection של בעלונים לצרכן על עדכון בעלון לרופא ובעלונים לצרכן של
:solution for injection**המרכיב הפעיל:**

ETANERCEPT 25 mg/0.5 ml; ETANERCEPT 50 mg/ml

צורת מינון:

Solution for injection

התוויה:**Rheumatoid arthritis**

Enbrel is indicated for the treatment of active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs (DMARDs) including methotrexate (unless contraindicated) has been inadequate.

Enbrel can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.

Reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis.

Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function.

Juvenile idiopathic arthritis

Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.

Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.

Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy.

Enbrel has not been studied in children aged less than 2 years.

Psoriatic arthritis

Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease.

Axial spondyloarthritis**Ankylosing spondylitis(AS)**

Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.

Non-radiographic axial spondyloarthritis

Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs).

Plaque psoriasis

Treatment of adults patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Paediatric plaque psoriasis

Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.

להלן העדכונים העיקריים בעלון לרופא:

4.8 UNDESIRABLE EFFECTS

Tabulated list of adverse reactions

The following list of adverse reactions is based on experience from clinical trials in adults and on postmarketing experience.

Within the organ system classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: very common ($\geq 1/10$); common ($\geq 1/100$ to $< 1/10$); uncommon ($\geq 1/1,000$ to $< 1/100$); rare ($\geq 1/10,000$ to $< 1/1,000$); very rare ($< 1/10,000$); not known (cannot be estimated from the available data).

System Organ Class	Very Common $\geq 1/10$	Common $\geq 1/100$ to $< 1/10$	Uncommon $\geq 1/1,000$ to $< 1/100$	Rare $\geq 1/10,000$ to $< 1/1,000$	Very Rare $< 1/10,000$	Frequency Not Known (Cannot be Estimated from Available Data)
Neoplasms benign, malignant and unspecified (including cysts and polyps)			Non-melanoma skin cancers* (see section 4.4)	Malignant melanoma (see section 4.4), lymphoma, leukaemia		Merkel cell carcinoma (see section 4.4), Kaposi's sarcoma

...

להלן העדכונים העיקריים בעלון לצרכן:

4. תופעות לוואי

כמו בכל תרופה, השימוש באנברלTM עלול לגרום לתופעות לוואי בחלק מהמשתמשים. אל תיבהל למקרא רשימת תופעות הלוואי. יתכן ואתה/הילד לא תסבול/יסבול מאף אחת מהן.

...

תופעות לוואי ששכיחותן אינה ידועה:

- סרקומה ע"ש קפוזי, Kaposi's sarcoma (סרטן נדיר הקשור לזיהום עם 8 human herpes virus. סרקומה ע"ש קפוזי לרוב מופיעה כנגעים סגולים על העור)

...

אם הופיעה תופעת לוואי, אם אחת מתופעות הלוואי מחמירה, או כאשר אתה סובל מתופעת לוואי שלא צוינה בעלון, עליך להתייעץ עם הרופא.

השינויים המודגשים ברקע צהוב מהווים החמרה. כמו כן, בוצעו שינויים נוספים הכוללים תוספת מידע, השמטת מידע ועדכוני נוסח שאינם מהווים החמרה. העלוונים המעודכנים זמינים באתר משרד הבריאות.

<https://data.health.gov.il/drugs/index.html#!/byDrug>

לחילופין, לקבלת עלון מלא מודפס ניתן לפנות לחברת פיזור פרמצבטיקה ישראל בע"מ, שנקר 9, ת.ד. 12133 הרצליה פיתוח, 46725.

בברכה,
מרגריטה פולישצ'וק
רוקחת ממונה